Introduction: BRAF V600E activating mutation is the most frequent genetic abnormality in the pathogenesis of papillary thyroid carcinoma. We aimed to evaluate the association between BRAF V600E mutation and well-established prognostic clinicopathological characteristics as well as iodine exposure. Material and methods: From 2000 to 2012, the data of PTC patients admitted to Dr. Lutfi Kirdar Kartal Education and Research Hospital in Turkey were reviewed retrospectively. Clinicopathological parameters were collected. BRAF V600E mutation was analysed by DNA sequencing method in tumour specimens. We hypothesised that BRAF V600E mutation prevalence is positively correlated with prolonged iodine exposure and expected to be higher in the second half of the recruitment period due to the increment in time spent from the iodisation process of the table salt in our country. Thus, iodine exposure was categorised as short-term (2000)(2001)(2002)(2003)(2004)(2005)(2006) and long-term (2006-2012). Results: A total of 197 patients were accrued. The study population predominantly consisted of conventional variant. A statistically significant relationship was observed between BRAF V600E mutation presence and age (p = 0.03), conventional variant PTC (p = 0.00002), T4 stage (p = 0.002), vascular invasion (p = 0.036), thyroid capsule invasion (p < 0.00001), extrathyroidal tissue invasion (p < 0.00001), and lymph node metastasis (p < 0.00001). When categorised as long-term and short-term, iodine exposure was not statistically significantly related with BRAF V600E mutation; however, there were far more PTC cases in the long-term group (86.3% vs. 13.7%).
Introduction
Thyroid carcinoma is the most frequent type of endocrine-borne malignancies. Papillary thyroid carcinoma (PTC) and follicular thyroid carcinoma (FTC), which are derived from follicular cells and C-cell-derived medullary thyroid carcinoma, are the common subtypes. Anaplastic type is the rarest variant and is highly aggressive [1] .
Differentiated thyroid carcinomas, PTC and FTC, are slow-growing cancers. Early-stage disease can be treated successfully with surgical excision. Patients with disseminated disease eventually die from their cancer, although the majority survive for years, which is an uncommon circumstance for many other advanced-stage malignancies.
An understanding of thyroid cancer pathogenesis remains critical for the prevention of the disease occurrence and for the development of targeted therapies directed against the causative pathway in the care of patients with advanced disease. Contributory genetic abnormalities have been defined to cause different subtypes of thyroid cancer. Frequent genetic abnormalities associated with PTC are the BRAF activating mutations, fusion oncogene RET/PTC, and NTRK rearrangements. BRAF V600E activating mutation, which occurs in 29-83% of tumours, is the most common mutation in PTC. BRAF is the downstream target of RAS in the mitogen-activated protein kinase (MAPK) signalling pathway. Following activation, RAF interacts with MEK and initiates phosphorylation of ERK kinase leading its activation. Activated ERK mediates the transcription Dr. Serhat Özçelik, Endocrinology and Metabolism Section, Haydarpaşa Education and Training Hospital, Istanbul, Turkey, tel: (+90) 505 923 13 67, fax: (+90) 216 336 05 65; e-mail: ozserhat1981@gmail.com  BRAF V600E mutation in papillary thyroid cancer Serhat Özçelik et al.
our country. Thus, iodine exposure was categorised as short-term (2000) (2001) (2002) (2003) (2004) (2005) (2006) and long-term (2006) (2007) (2008) (2009) (2010) (2011) (2012) .
Method

DNA Isolation
Genomic DNA was extracted from 8-10 μm sections of formalinfixed and paraffin-embedded (FFPE) PTC tissue samples, starting with deparaffinisation using conventional xylene/ethanol treatment, one-hour incubation with proteinase K, and subsequent DNA purification utilising the QIAampDNA FFPE tissue kit (Qiagen, USA) according to the manufacturer's instructions. Following the DNA isolation, DNA were archived at -20°C in a freezer until the start of the study.
PCR and DNA sequencing
In order to detect the mutations at exon 15 of the BRAF gene, PCR was performed with the following forward and reverse primers as described by Qu 
Statistical analysis
All statistical analyses were carried out using SPSS 17.0 version (IBM Corp., Armonk, NY, USA). Characteristics of patients were evaluated with descriptive analysis. Chi-squared test and Fisher's exact test were used in order to compare the clinicopathological features as well as the iodine exposure status, between BRAF V600E -positive and -negative subgroups. P values below 0.05 were accepted as statistically significant. of many genes, which promotes cellular growth and survival [2] [3] [4] [5] . Radiation exposure and iodine excess are the best-known predisposing factors for the development of PTC [6, 7] . There is some evidence that high iodine exposure may be a driver event for transforming BRAF to a constitutively active state [7] . In Turkey, iodisation of table salt was practised in 1999 and fully carried out in 2002 [8] [9] [10] . Duration of time from the iodisation process may be an indirect measure of iodine exposure.
Extensive data suggest that BRAF V600E mutation is associated with a poorer prognosis compared to PTC without harbouring the BRAF V600E mutation. It appears to be associated with increased risk of extrathyroidal tumour extension, lymph node metastases, and recurrence [7] . In this study, we aimed to describe the relation of iodine exposure, if any, as well as the clinicopathological factors with BRAF V600E mutation.
Material and methods
Study oversight
This study was conducted in compliance with the ethical principles according to the Declaration of Helsinki, and it was approved by the local Institutional Review Board (April 8, 2014). Data of PTC patients admitted to Dr. Lutfi Kirdar Kartal Education and Research Hospital were reviewed retrospectively. A total of 197 patients (159 females and 38 males; median age 46, range 17-86 years) with PTC were screened for BRAF V600E mutation in this study from October 2000 to October 2012. Other clinicopathological features including PTC variant, tumour size, T stage, necrosis, calcification, vascular invasion, tumour capsule status and invasion, extrathyroidal invasion, multicentricity, and concomitant pathology in thyroid tissue were collected. Trials conducted in an effort to define the iodine status in the Turkish population, with the use of urinary iodine excretion, are presented in Table I . Urinary iodine excretion was not evaluated in our study. Using the national studies as the basis for the iodine status of the study population, we principally aimed to look for the concept of relative increment in iodine exposure [8] [9] [10] [11] . We hypothesised that BRAF V600E mutation prevalence is positively correlated with increasing iodine exposure and is expected to be higher in the second half of the recruitment period (2006 to 2012) due to the increment in exposure time spent from the iodisation process of table salt in Table I 
. An overview of the iodine status screening trials in the Turkish population
Results
Patient characteristics
A total of 197 patients with PTC were screened for BRAF V600E mutation in this study. Characteristics of patients are summarised in Table II 
BRAF V600E mutation
BRAF V600E mutation frequency was found to be 22.8% (45/197) in this study. Association of BRAF V600E mutation with clinical and pathological parameters is detailed in Table III . A statistically significant relationship was observed between BRAF V600E mutation presence and conventional variant PTC (p = 0.00002), T4 stage (p = 0.002), vascular invasion (p = 0.036), thyroid capsule invasion (p < 0.00001), extrathyroidal tissue invasion (p < 0.00001), and lymph node metastasis (p < 0.00001). Age, for the cut-off level, 45 (7 th TNM), was not significantly associated with BRAF V600E mutation whereas age, for the cut-off level of 55 (8 th TMN), was significantly associated with mutation status (p = 0.03). The extratumoural thyroid background, tumour necrosis and capsule formation were not significantly associated with BRAF V600E mutation. When grouped in two, iodine exposure, was not statistically significantly related with BRAF V600E mutation; however, there were more PTC cases in the long-term group compared to short-term (86.3% vs. 13.7%).
Rare BRAF mutations
Along with BRAF V600E mutation, BRAF F583Y , BRAF F595L , and BRAF V600V were also detected in the study group. 
ORIGINAL PAPER
The BRAF F583Y was found in four conventional variants of PTC. Tumours with BRAF F83Y mutation were macrocarcinomas, all of which had thyroid capsule invasion, soft tissue invasion, and lymph node metastasis. The identified BRAF F595L mutation in the oncocytic variant of PTC was a macrocarcinoma with thyroid capsule and soft tissue invasion. Lastly, the BRAF V600V mutation was estimated as one in each of the conventional, follicular, and oncocytic variants (Fig. 1 ). Regarding this mutation arising from three different PTC variants, the conventional one was microcarcinoma whereas follicular and oncocytic variants were noted as macrocar-cinoma (Tab. IV). All these mutations were previously reported, and they were not directly associated with the constitutive activation of the BRAF protein. But it is reported that BRAF F595L mutation is a gain-of-function variant with intermediate activity that does not act paradoxically, but cooperates with mutant RAS to promote oncogenic signalling [14, 15] .
Discussion
Papillary thyroid carcinoma is the most frequently encountered malignant thyroid tumour. Although cu- rative treatment options for advanced disease are still lacking, rapid progress has been made over the years in understanding the molecular mechanisms underlying PTC tumorigenesis and progression. Among the genetic abnormalities, activating BRAF V600E in the mitogen activated protein kinase pathway is the most commonly observed mutation, with a prevalence of 29-83% [2] [3] [4] [5] . In the current study, we evaluated the BRAF V600E mutation prevalence and its association with clinicopathological characteristics and a potential environmental causative agent of BRAF V600E, iodine exposure. The presence of BRAF V600E mutation portends a worse prognosis in many series [16] [17] [18] . In an analysis of 314 patients, those with a BRAF V600E mutation had a significantly worse outcome than did those with a wild-type BRAF [19] . Higher rates of recurrent and persistent disease were observed. Similarly, a recent metanalysis [16] involving 2247 patients found a higher likelihood of recurrent disease in BRAF V600E -positive patients. A retrospective multicentre study by Xing et al. revealed poorer recurrence-free survival in mutation-positive patients [20] . The impact of BRAF V600E mutation on survival could not be addressed in the present study because most of the patients were lost to follow-up.
Despite the scant evidence on survival due to the necessity of longer follow-up time, abundant data is available regarding clinicopathological factors and BRAF V600E relation. Xing et al., in their review, reported that BRAF V600E was associated with extrathyroidal invasion, lymph node metastasis, and advanced surgical stage [21] . Our findings, in addition to these three parameters that have been confirmed to be poor prognostic by almost all studies, indicate that conventional variant and vascular invasion were positively associated with BRAF V600E mutation. The specific histological variant being a high-risk feature was compatible with the results of Lee et al., who reported that BRAF V600E mutation was most frequent in tall-cell followed by conventional variant [22] . There were no tall cell variants in the present study. However, follicular and oncocytic variants existed and had lower frequencies of mutation than the conventional variant. In accordance with our findings, Smith et al., in their analysis investigating whether mutation rates differ between conventional versus follicular variant, found that BRAF V600E mutation is significantly more common in conventional variant PTC [23] . Another study by Nikiforova et al. came to same conclusion, finding an impact of BRAF V600E on the incidence of unfavourable prognostic factors including classic and tall cell variant histology and advanced stage [24] . The authors also noted that older age was correlated with mutation positivity. Likewise, > 45 years of age at diagnosis was shown to have close association with BRAF V600E in the study by Lu et al. [25] . On the other hand, the current study failed to show the same, but, adjusting the cut-off level to 55 years according to the current TNM staging, our results were also consistent with the previous studies. Older age at diagnosis (> 55) was correlated with BRAF V600E mutation presence.
In a recent study from China, 1032 patients were evaluated. The authors ended up with 54.6% BRAF V600E mutation, which was significantly associated with extrathyroidal extension and advanced TNM stage [7] . They also concluded that thyroid background of Hashimoto thyroiditis (HT) and lymphocytic thyroiditis (LT) were negatively correlated with mutation presence. Lim et al., by a single-centre experience with 3130 cases, reported a similar result, observing that PTC with a background of LT was significantly lower in those with the BRAF V600E mutation compared with those with wild-type BRAF [26] . In another study exploring BRAF V600E mutation as a predictor for central nodal metastasis, HT emerged as an independent protective factor. In the current study we found no significant association with thyroid background and BRAF V600E mutation. However, the frequency of BRAF V600E mutation was remarkably low (22.8%) compared to both previous reports [27] and the above-mentioned data, in which mutation rates were 54.6%, 74.3%, and 75.3%, respectively. The difference might be attributable to the diverse histological variant composition across the studies. The current study involved 34.5% of follicular variant PTC. A study by Navarro et al., involving a much lower percentage of follicular variants (4.6%) than our study, identified a relatively low ratio of BRAF V600E mutations (38.4%) compared to existing literature [28] . Another possible explanation for this could be the heterogeneity in selected populations and the mutation analysis techniques.
In a study conducted in the Irish population, the prevalence of BRAF V600E mutation, compared to the RET/ PTC mutation in PTC, was higher than previously, and the authors suspected that this might be due to an environmental factor [29] . At least some data suggest potential association with high iodine intake and BRAF V600E . The available data are conflicting, with some suggesting positive and others negative or no relation.
In the first study analysing iodine status in Turkey conducted from 1997 through 1999, median urinary iodine concentration of the various regions was noted as 36 μg/L; the follow-up study, in 2007, evaluated the performance of the iodisation of table salt and showed that the median urinary iodine amount increased to 130 μg/L. Considering these data as a guide, our study, undertaken between 2000 and 2012, did not address the urinary iodine concentration, but aimed at looking for the impact of "relative increment in iodine exposure" on BRAF mutation. We defined the exposure as the time spent from the iodisation process of table salt in ORIGINAL PAPER our country and dichotomised into short-term and long-term, according to whether the PTC was diagnosed in the first or second half of the study period. The trials had different designs on defining iodine exposure. In one study, the authors compared the prevalence of the BRAF V600E mutation in classical PTC of 1032 patients from five regions in China that harbour different iodine content in natural drinking water [7] . They argued that high iodine intake may be a risk factor for PTC because the prevalence of BRAF V600E mutation was significantly higher in regions with high iodine content than any of the regions with normal iodine content. Contrary to this finding, in the present study, there was no significant association between long-term iodine exposure and BRAF V600E . However, the iodine content of drinking water in the previous trial was far above the amount used for prophylaxis in table salt. Additionally, the authors speculated that the worldwide increment in the frequency of PTC is the consequence of rising iodine support, but this should be interpreted cautiously. More extensive utility of thyroid ultrasonography and fine-needle aspiration biopsy compared to previous years may have an effect on the rise in incidence. In support of this, we experienced far more PTC cases in the second half of our study period.
On the other hand, investigators at Harvard Medical School noted that, on exposure with excess iodine, rat thyroid follicular cells that conditionally express BRAF V600E showed a decrease in BRAF V600E -induced up-regulation of miR-17-92, blocking NOTCH signalling, which confers proliferative advantage. Overall, this study shows that high iodine exerts a protective influence overBRAF V600E -activated thyroid cells. Iodine might reduce acute BRAF V600E oncogene induction and activity [30] . Frasca et al. recently examined the relationship of BRAF V600E mutation in PTC with iodine intake in some regions in Italy. The authors found BRAF V600E mutation in 107 of 270 cases in an iodine-sufficient region (40%) vs. 18 of 53 cases of PTC in an iodine-deficient region (34%), which was, similarly to our study, statistically insignificant [31] .
This study had some features that might be viewed as potential weaknesses. First, selection bias might have been introduced due to the retrospective nature of the study. Second, follow-up data do not exist, thus we are unable to comment on whether the findings translate into outcome measures. Lastly, the sample size is small.
Conclusion
The results of our retrospective study provide evidence suggesting that BRAF V600E mutation is correlated with unfavourable prognostic features. The results also challenge existing assumptions about the high iodine exposure and BRAF mutation incidence, demonstrating no association.
